Article

Using a Distribution-Based Approach and Systematic Review Methods to Derive Minimum Clinically Important Differences

2020-12-04

Abstract excerpt

<h4>Background: </h4> Clinical interpretation of changes measured on a scale is dependent on knowing the minimum clinically important difference (MCID) for that scale: the threshold above which clinicians, patients, and researchers perceive an outcome difference. Until now, approaches to determining MCIDs were based upon individual studies or surveys of experts. However, the comparison of meta-analytic treatment e...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2bd522ca-ea63-5af3-b8d4-6743d513875f
DOI: 10.21203/rs.3.rs-114299/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Using a Distribution-Based Approach and Systematic Review Methods to Derive Minimum Clinically Important DifferencesDOI 10.21203/rs.3.rs-114299/v1Read

Treatment effects of pharmacotherapy and non-pharmacotherapy of Alzheimer dementia: A systematic review overview and updated network meta-analysis.Semantic proximity Read

The Comparability of Manual vs. Algorithm-Based Calculation of Clinical Trial Methodological Quality IndicesSemantic proximity Read

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read

Risk of Bias in Clinical Psychology Meta-Analyses (2000-2020): An OverviewSemantic proximity Read

Advanced statistical methods in meta-analysis with applications in preclinical neurological drug discovery dataSemantic proximity Read

Project Rebuild the Evidence Base (REB): a method to interpret randomised clinical trials and their meta-analysis to present solid benefit-risk assessments to patients.Semantic proximity Read

Development of a Core Outcome Set for Mild Cognitive Impairment (MCI-COS): Recommendations from a multistakeholder Delphi consensus studySemantic proximity Read

Using Real-World Data to Rationalize Clinical Trials Eligibility Criteria Design: A Case Study of Alzheimer’s Disease TrialsSemantic proximity Read

Treatment recommendations based on Network Meta-Analysis: rules for risk-averse decision-makersSemantic proximity Read

Extension of individual model averaging assessments to unbalanced designs and dose-responseSemantic proximity Read

Adjudicating mild cognitive impairment due to Alzheimer’s disease as a novel endpoint event in the TOMMORROW prevention clinical trialSemantic proximity Read

Reducing placebo response in clinical trials of agitation in Alzheimer’s diseaseSemantic proximity Read